STOCK TITAN

Dianne Whitfield reports planned stock sales — TARS (NASDAQ: TARS)

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Dianne C. Whitfield filed a Form 144 reporting proposed sales of Common Stock. The filing lists three transactions: 15,565 shares on 01/02/2026 (proceeds $1,255,687.45), 4,029 shares on 03/17/2026 (proceeds $279,671.82), and 4,071 shares on 03/18/2026 (proceeds $279,717.60).

The broker on the notice is Fidelity Brokerage Services LLC. The filing includes a separate line noting Restricted Stock Vesting dated 03/18/2026.

Positive

  • None.

Negative

  • None.

Insights

Rule 144 notice for proposed resale of shares by an affiliate; transaction details are routine disclosure.

Form 144 is a required notice when affiliates or certain holders intend to sell restricted or control securities. The filing lists exact share counts and cash amounts for each reported sale, and names Fidelity Brokerage Services LLC as the broker.

The legal condition of these shares (restricted stock vesting noted on 03/18/2026) matters for resale eligibility; timing and actual execution depend on compliance with Rule 144 resale conditions and market arrangements.

Reported volumes are modest relative to typical public-company floats; these are straightforward offering notices.

The filing separately lists three proposed dispositions with proceeds shown in dollars. Broker identification is provided, which is standard for routing proposed sales through a broker-dealer.

Actual market impact depends on whether and when the listed shares are sold; the filing documents intent, not completed market trades.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the Form 144 for TARS disclose?

It disclosed proposed sales of Common Stock by Dianne C. Whitfield on three dates. The filing lists 15,565 shares on 01/02/2026, 4,029 shares on 03/17/2026, and 4,071 shares on 03/18/2026, with corresponding proceeds shown.

Who is the broker listed on the TARS Form 144?

The broker-dealer listed is Fidelity Brokerage Services LLC. The filing lists the broker's address and connection to the proposed transactions for routing any brokered sales of the reported shares.

Do the amounts in the Form 144 represent completed sales?

No; the Form 144 reports proposed or intended sales under Rule 144. The filing shows share counts and proceeds but does not by itself prove the transactions were executed in the market.

What does the "Restricted Stock Vesting" entry mean on the filing?

The filing includes a line labeled Restricted Stock Vesting dated 03/18/2026. This indicates a compensation-related vesting event was recorded in the filing as part of the securities information.

Are the dollar proceeds in the Form 144 the sale prices or estimates?

The filing lists dollar amounts next to each share count, shown as proceeds for the reported entries. These figures are the amounts included in the notice rather than market execution confirmations.
Tarsus Pharmaceuticals, Inc.

NASDAQ:TARS

View TARS Stock Overview

TARS Rankings

TARS Latest News

TARS Latest SEC Filings

TARS Stock Data

2.84B
40.38M
Biotechnology
Biological Products, (no Diagnostic Substances)
Link
United States
IRVINE